Detail of "110044-82-1"

Reference

N-Acetyl-leucinyl-leucinyl-norleucinal inhibits lipopolysaccharide-induced NF-kB activation and prevents TNF and IL-6 synthesis in vivo

N-Acetyl-leucinyl-leucinyl-norleucinal inhibits lipopolysaccharide-induced NF-kB activation and prevents TNF and IL-6 synthesis in vivo. Schow, Steven R.; Joly, Alison (CV Therapeutics, Inc., Palo Alto, CA 94304, USA). Cellular Immunology, 175(2), 199-202 (English) 1997 Academic. CODEN: CLIMB8. ISSN: 0008-8749. DOCUMENT TYPE: Journal CA Section: 15 (Immunochemistry) The effects of N-acetyl-leucinyl-leucinyl-norleucinal (ALLN), a potent inhibitor of proteolysis catalyzed by proteasomes, on the activation of NF-kB in vitro and in vivo have been examd. Confirming earlier observations, ALLN inhibits the activation of NF-kB in macrophage cultures stimulated with LPS, resulting in the intracellular accumulation of IkB and p105. The synthesis of TNF, a reaction dependent upon NF-kB activation, is blocked by ALLN. Treatment of mice with LPS results in the induction of TNF and IL-6 within 90 min followed by lethal shock at 24 h. 110044-82-1 and 140879-24-9 which are cas registry numbers of chemicals are mentioned. In mice pretreated with LLN, serum TNF and IL-6 levels were significantly lower than those in untreated animals. These studies suggest that the proteasome is a novel target for the identification of agents that may be useful in the treatment of those diseases whose etiol. is dependent on the activation of NF-kB. .

Use of a proteasome inhibitor in the treatment of fibrotic diseases

Use of a proteasome inhibitor in the treatment of fibrotic diseases.Several substances are used for example 110044-82-1 and 134381-21-8 which are their cas registry numbers. Stangl, Karl; Meiners, Sike; Hocher, Berthold (Charite-Universitats Medizin Berlin, Germany). PCT Int. Appl. WO 2004011019 A1 5 Feb 2004, 35 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (German). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K038-00. APPLICATION: WO 2003-EP8205 25 Jul 2003. PRIORITY: DE 2002-10233929 25 Jul 2002. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) The invention relates to the use of at least one proteasome inhibitor, preferably in the form of a threonine protease inhibitor, in the treatment of fibrotic diseases, esp. fibrotic diseases of the cardiovascular system. .